HomeCompareVSBSX vs JNJ

VSBSX vs JNJ: Dividend Comparison 2026

VSBSX yields 3.57% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $5.1K in total portfolio value· pulled ahead in Year 9
10 years
VSBSX
VSBSX
● Live price
3.57%
Share price
$19.51
Annual div
$0.70
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.2K
Annual income
$449.67
Full VSBSX calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — VSBSX vs JNJ

📍 JNJ pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVSBSXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VSBSX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VSBSX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VSBSX
Annual income on $10K today (after 15% tax)
$303.75/yr
After 10yr DRIP, annual income (after tax)
$382.22/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,603.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VSBSX + JNJ for your $10,000?

VSBSX: 50%JNJ: 50%
100% JNJ50/50100% VSBSX
Portfolio after 10yr
$27.7K
Annual income
$2,569.53/yr
Blended yield
9.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VSBSX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VSBSX buys
0
JNJ buys
0
No recent congressional trades found for VSBSX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVSBSXJNJ
Forward yield3.57%2.13%
Annual dividend / share$0.70$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$25.2K$30.3K
Annual income after 10y$449.67$4,689.40
Total dividends collected$4.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VSBSX vs JNJ ($10,000, DRIP)

YearVSBSX PortfolioVSBSX Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,057$357.36$10,592$272.30+$465.00VSBSX
2$12,201$369.29$11,289$357.73+$912.00VSBSX
3$13,436$380.82$12,123$472.89+$1.3KVSBSX
4$14,768$391.93$13,141$629.86+$1.6KVSBSX
5$16,204$402.61$14,408$846.81+$1.8KVSBSX
6$17,751$412.87$16,021$1,151.60+$1.7KVSBSX
7$19,417$422.70$18,122$1,588.22+$1.3KVSBSX
8$21,208$432.11$20,930$2,228.20+$278.00VSBSX
9← crossover$23,134$441.09$24,792$3,191.91$1.7KJNJ
10$25,203$449.67$30,274$4,689.40$5.1KJNJ

VSBSX vs JNJ: Complete Analysis 2026

VSBSXStock

This fund employs an indexing investment approach designed to track the performance of the Bloomberg US Treasury 1–3 Year Bond Index. This Index includes fixed income securities issued by the U.S. Treasury (not including inflation-protected securities), all with maturities between 1 and 3 years. Like other bond funds, one of the fund’s risks is that increases in interest rates cause the prices of the bonds in the portfolio to decrease; however, such risk is less pronounced in this fund than in funds with longer average durations. A key risk of the fund is the fact that changes in interest rates can eventually lead to a decrease in income for the fund. The fund has a reduced risk of default, since the bonds in the portfolio are backed by the full faith and credit of the U.S. government. Investors with short-term savings goals who are willing to accept some price movement may wish to consider this fund.

Full VSBSX Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this VSBSX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VSBSX vs SCHDVSBSX vs JEPIVSBSX vs OVSBSX vs KOVSBSX vs MAINVSBSX vs ABBVVSBSX vs MRKVSBSX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.